All In Biotech

NDA 018948 · Leadiant Biosci INC

Carnitor

Levocarnitine · Oral · Carnitine Analog

NovelPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Apr 17, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1985

Dec 27, 1985

Approved uses

2

Original approval plus efficacy supplements

Registered trials

188

46 Phase 3, 12 recruiting

FAERS reports

3,646

2,818 serious, 395 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 30, 2024.

INDICATIONS AND USAGE CARNITOR ® (levocarnitine) is indicated in the treatment of primary systemic carnitine deficiency. In the reported cases, the clinical presentation consisted of recurrent episodes of Reye-like encephalopathy, hypoketotic hypoglycemia, and/or cardiomyopathy. Associated symptoms included hypotonia, muscle weakness and failure to thrive. A diagnosis of primary carnitine deficiency requires that serum, red cell and/or tissue carnitine levels be low and that the patient does not have a primary defect in fatty acid or organic acid oxidation (see CLINICAL PHARMACOLOGY ). In some patients, particularly those presenting with cardiomyopathy, carnitine supplementation rapidly alleviated signs and symptoms. Treatment should include, in addition to carnitine, supportive and other therapy as indicated by the condition of the patient. CARNITOR ® (levocarnitine) is also indicated for acute and chronic treatment of patients with an inborn error of metabolism which results in a secondary carnitine deficiency.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 16, 1992 Supplement 9 · Efficacy
  • Dec 27, 1985 Original approval · Type 1 - New Molecular Entity · priority review Review
2 products under this application
  • CARNITOR · LEVOCARNITINE 1GM/10ML · SOLUTION, ORAL · Discontinued
  • CARNITOR · LEVOCARNITINE 330MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Levocarnitine" as an intervention, any sponsor and status, largest first.

All 188 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • seizure391
  • off label use309
  • vomiting230
  • diarrhoea210
  • drug ineffective195
  • fatigue185
  • pneumonia182
  • pyrexia174
  • nausea135
  • product dose omission issue133
  • somnolence131
  • decreased appetite123

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200423
200517
200612
200728
200853
200932
201030
201134
201257
201371
201480
2015124
2016226
2017159
2018195
2019228
2020271
2021255
2022356
2023411
2024408
2025353
2026223

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Carnitor (Levocarnitine (With Sugar))

2024 spending

$46K

Beneficiaries

18

113 claims

Per beneficiary

$2,552

$0.35 per unit

View as table
YearSpending
2020$67,696
2021$55,647
2022$55,240
2023$55,962
2024$45,944

Part D: Carnitor* (Levocarnitine)

2024 spending

$226K

Beneficiaries

205

981 claims

Per beneficiary

$1,101

$1.89 per unit

View as table
YearSpending
2020$451,470
2021$387,772
2022$543,715
2023$442,821
2024$225,745

Part B: Carnitor* (Levocarnitine*) · HCPCS J1955

2024 spending

$3.4M

Beneficiaries

1,549

23,222 claims

Per beneficiary

$2,214

2024 ASP limit $32.18 per unit

View as table
YearSpending
2020$4,611,342
2021$16,231,026
2022$11,067,747
2023$5,607,416
2024$3,428,722

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 46 on PubMed

Sponsor: Leadiant Biosci INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.